<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tolterodine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01036</strong>&#160; (APRD00146)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01036/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01036/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01036.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01036.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01036.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01036.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01036.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01036">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(+)-(R)-2-(alpha-(2-(Diisopropylamino)ethyl)benzyl)-p-cresol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>(+)-Tolterodine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tolterodina</td><td>Spanish</td><td>INN</td></tr><tr><td>Tolterodinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Tolterodine Tartrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000467/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000467/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: TWHNMSJGYKMTRB-KXYUELECSA-N</li>
              <li>Monoisotopic Mass: 475.257002543</li>
              <li>Average Mass: 475.5745</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000467">DBSALT000467</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Detrol</td><td>Pfizer</td></tr><tr><td>Detrusitol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/muscarinic-antagonists">Muscarinic Antagonists</a></li>
<li><a href="/mesh/anti-incontinence-agents">Anti-Incontinence Agents</a></li>
<li><a href="/mesh/antispasmodics">Antispasmodics</a></li>
<li><a href="/mesh/muscle-relaxants-genitourinary">Muscle Relaxants, Genitourinary</a></li></ul></td></tr><tr><th>CAS number</th><td>124937-51-5</td></tr><tr><th>Weight</th><td>Average: 325.4876<br>Monoisotopic: 325.240564619</td></tr><tr><th>Chemical Formula</th><td>C<sub>22</sub>H<sub>31</sub>NO</td></tr><tr><th>InChI Key</th><td>OOGJQPCLVADCPB-HXUWFJFHSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Diphenylmethanes</td></tr><tr><th>Direct parent</th><td>Diphenylmethanes</td></tr><tr><th>Alternative parents</th><td>Phenylpropylamines; Para Cresols; Toluenes; Tertiary Amines; Polyamines; Enols</td></tr><tr><th>Substituents</th><td>phenylpropylamine; p-cresol; toluene; phenol derivative; tertiary amine; enol; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).</td></tr><tr><th>Pharmacodynamics</th><td>Tolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically active metabolite. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity similar to that of tolterodine, contributes significantly to the therapeutic effect. Both tolterodine and the 5-hydroxymethyl metabolite exhibit a high specificity for muscarinic receptors, since both show negligible activity or affinity for other neurotransmitter receptors and other potential cellular targets, such as calcium channels. Tolterodine has a pronounced effect on bladder function. The main effects of tolterodine are an increase in residual urine, reflecting an incomplete emptying of the bladder, and a decrease in detrusor pressure, consistent with an antimuscarinic action on the lower urinary tract.</td></tr><tr><th>Mechanism of action</th><td>Both tolterodine and its active metabolite, 5-hydroxymethyltolterodine, act as competitive antagonists at muscarinic receptors. This antagonism results in inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>113 &#177; 26.7 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>Approximately 96.3%.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Tolterodine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00142">N-Dealkylated tolterodine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/142">Details</a></td></tr><tr><td>Tolterodine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00143">5-Hydroxymethyl tolterodine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/143">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00142">N-Dealkylated tolterodine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01256">N-Dealkylated 5-hydroxymethyl tolterodine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1413">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00143">5-Hydroxymethyl tolterodine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01256">N-Dealkylated 5-hydroxymethyl tolterodine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1414">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00143">5-Hydroxymethyl tolterodine</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01257">5-Carboxylic acid tolterodine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1415">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Following administration of a 5-mg oral dose of 14C-tolterodine solution to healthy volunteers, 77% of radioactivity was recovered in urine and 17% was recovered in feces in 7 days.</td></tr><tr><th>Half life</th><td>1.9-3.7 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.958</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9194</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8286</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6727</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8305</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.6904</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6235</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8918</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7408</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.8139</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6965</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.7456</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5853</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8575</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5259</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6658
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7967
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9959
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5503 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8014
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6875
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pharmacia and upjohn co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>Vangard Labs Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule, extended release</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Amiodarone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may decrease the metabolism and clearance of Tolterodine. Adjust the Tolterodine dose and monitor for efficacy and toxicity. </td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>Aprepitant may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may decrease the metabolism and clearance of Tolterodine. Adjust the Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00201">Caffeine</a></td><td>Caffeine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Chlorpromazine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. </td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01012">Cinacalcet</a></td><td>Cinacalcet may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. </td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Clarithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00257">Clotrimazole</a></td><td>Clotrimazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00907">Cocaine</a></td><td>Cocaine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Conivaptan may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Cyclosporine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01264">Darunavir</a></td><td>Darunavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Delavirdine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Desipramine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Diltiazem may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>Doxycycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>Efavirenz may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Etravirene may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may decrease the metabolism and clearance of tolterodine. Adjust tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Fluoxetine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. </td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Fosamprenavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Haloperidol may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Imatinib may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Isoniazid may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01259">Lapatinib</a></td><td>Lapatinib may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00281">Lidocaine</a></td><td>Lidocaine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01601">Lopinavir</a></td><td>Lopinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00916">Metronidazole</a></td><td>Metronidazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01110">Miconazole</a></td><td>Miconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Nefazodone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00622">Nicardipine</a></td><td>Nicardipine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
</td></tr><tr><td><a href="/drugs/DB01059">Norfloxacin</a></td><td>Norfloxacin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Paroxetine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. </td></tr><tr><td><a href="/drugs/DB01186">Pergolide</a></td><td>Peroglide may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. </td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Posaconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00761">Potassium Chloride</a></td><td>The ulcerative effects of solid oral dosage forms of KCl may be enhanced by the anticholinergic, Tolterodine. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.</td></tr><tr><td><a href="/drugs/DB01278">Pramlintide</a></td><td>Additive reduction in gut motility may occur. Consider alternate therapy or use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Quinidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Ranolazine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Saquinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00021">Secretin</a></td><td>The stimulatory effect of Secretin may be reduced by anticholinergics such as Tolterodine. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.</td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Sertraline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB06268">Sitaxentan</a></td><td>Sitaxsentan may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tolterodine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may reduce the metabolism and clearance of Tolterodine. Consider alternate therapy or monitor for therapeutic/adverse effects of Tolterodine if Terbinafine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>Tetracycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00662">Trimethobenzamide</a></td><td>Trimethobenzamide and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>Trospium and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>Vinblastine, a CYP3A4 inhibitor, may increase the serum concentration of Tolterodine by decreasing its metabolism. Poor CYP2D6 metabolizers metabolize Tolterodine via CYP3A4. A dose adjustment of Tolterodine may be required. Monitor for changes in the therapeutic/adverse effects of Tolterodine if Vinblastine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tolterodine by decreasing its metabolism. Tolterodine is mainly metabolized via the CYP2D6 pathway. This interaction is likely only a concern in patients who are poor CYP2D6 metabolizers. Monitor for changes in the therapeutic and adverse effects of tolterodine if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food.</li></ul></td></tr></tbody></table>